Evidence of involvement of leptin and IL-6 peptides in the action of interferon-beta in secondary progressive multiple sclerosis

Peptides

Volumn 26, Issue 11, 2005, Pages 2289-2293

  Angelucci, Francesco ^a   Mirabella, Massimiliano ^a   Caggiula, Marcella ^a   Frisullo, Giovanni ^a   Patanella, Katia ^a   Sancricca, Cristina ^a   Nociti, Viviana ^a   Tonali, Pietro Attilio ^a   Batocchi, Anna Paola ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

Cytokines; IL 6; Interferon beta; Leptin; Secondary progressive multiple sclerosis

Indexed keywords

GADOLINIUM PENTETATE; INTERFERON BETA SERINE; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 6; LEPTIN; METHYLPREDNISOLONE; PROTEIN P40;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DISABILITY; DISEASE COURSE; DRUG MECHANISM; FEMALE; HUMAN; HUMAN CELL; MALE; MULTIPLE SCLEROSIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PILOT STUDY; PRIORITY JOURNAL;

ADULT; BIOLOGICAL RESPONSE MODIFIERS; CASE-CONTROL STUDIES; FEMALE; HUMANS; INTERFERON-BETA; INTERLEUKIN-6; LEPTIN; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; PILOT PROJECTS; PREDICTIVE VALUE OF TESTS;

EID: 27744460153     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.peptides.2005.03.037     Document Type: Article

References (27)

1. A.P. Batocchi, M. Rotondi, M. Caggiula, G. Frisullo, F. Odoardi, and V. Nociti Leptin as a marker of multiple sclerosis activity in patients treated with interferon-beta J Neuroimmunol 139 2003 150 154
2. M. Bullo, P. Garcia-Lorda, I. Megias, and J. Salas-Salvado Systemic inflammation, adipose tissue tumor necrosis factor, and leptin expression Obes Res 11 2003 525 531
3. V. Chesnokova, and S. Melmed Minireview: neuro-immuno-endocrine modulation of the hypothalamic-pituitary-adrenal (HPA) axis by gp130 signaling molecules Endocrinology 143 2002 1571 1574
4. C. Confavreux, S. Vukusic, and P. Adeleine Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process Brain 126 2003 770 782
5. S.W. Coppack Pro-inflammatory cytokines and adipose tissue Proc Nutr Soc 60 2001 349 356
6. R. Faggioni, K.R. Feingold, and C. Grunfeld Leptin regulation of the immune response and the immunodeficiency of malnutrition FASEB J 15 2001 2565 2571
7. M.S. Freedman, and H.L. Atkins Suppressing immunity in advancing MS too much too late, or too late for much? Neurology 62 2004 168 169
8. E. Frohman, T. Phillips, K. Kokel, J. Van Pelt, S. O'Leary, and S. Gross Disease-modifying therapy in multiple sclerosis: strategies for optimizing management Neurologist 8 2002 227 236
9. G. Frisullo, F. Angelucci, M. Mirabella, M. Caggiula, K. Patanella, and V. Nociti Leptin enhances the release of cytokines by peripheral blood mononuclear cells from relapsing multiple sclerosis patients J Clin Immunol 24 2004 286 292
10. R. Furlan, A. Bergami, R. Lang, E. Brambilla, D. Franciotta, and V. Martinelli Interferon-beta treatment in multiple sclerosis patients decreases the number of circulating T cells producing interferon-γ and interleukin-4 J Neuroimmunol 111 2000 86 92
11. E. Jequier Leptin signaling, adiposity, and energy balance Ann NY Acad Sci 967 2002 379 388
12. L. Kappos, C. Polman, C. Pozzilli, A. Thompson, K. Beckmann, and F. Dahlke Final analysis of the European multicenter trial on IFN{beta}-1b in secondary-progressive MS Neurology 57 2001 1969 1975
13. L. Kappos Effect of drugs in secondary disease progression in patients with multiple sclerosis Mult Scler 10 Suppl 1 2004 S46 S54
14. M. Landt Leptin binding and binding capacity in serum Clin Chem 46 2000 379 384
15. H. Link The cytokine storm in multiple sclerosis Mult Scler 4 1998 12 15
16. C. Liu, X.J. Liu, G. Barry, N. Ling, R.A. Maki, and E.B. De Souza Expression and characterization of a putative high affinity human soluble leptin receptor Endocrinology 138 1997 3548 3554
17. G. Matarese, A. Di Giacomo, V. Sanna, G.M. Lord, J.K. Howard, and A. Di Tuoro Requirement for leptin in the induction and progression of autoimmune encephalomyelitis J Immunol 166 2001 5909 5916
18. G. Matarese, V. Sanna, A. Di Giacomo, G.M. Lord, J.K. Howard, and S.R. Bloom Leptin potentiates experimental autoimmune encephalomyelitis in SJL female mice and confers susceptibility to males Eur J Immunol 31 2001 1324 1332
19. F.E. Munschauer 3rd., and W.H. Stuart Rationale for early treatment with interferon beta-1a in relapsing-remitting multiple sclerosis Clin Ther 19 1997 868 882
20. V. Ozenci, M. Kouwenhoven, N. Teleshova, M. Pashenkov, S. Fredrikson, and H. Link Multiple sclerosis: pro- and anti-inflammatory cytokines and metalloproteinases are affected differentially by treatment with IFN-beta J Neuroimmunol 108 2000 236 243
21. J. Palace Clinical and laboratory characteristics of secondary progressive MS J Neurol Sci 206 2003 131 134
22. A. Parry, R. Corkill, A.M. Blamire, J. Palace, S. Narayanan, and D. Arnold Beta-interferon treatment does not alwyis slow the progression of axonal injury in multiple sclerosis J Neurol 250 2003 171 178
23. V. Sanchez-Margalet, C. Martin-Romero, C. Gonzalez-Yanes, R. Goberna, and J. Rodriguez-Bano Muniain MA: leptin receptor (Ob-R) expression is induced in peripheral blood mononuclear cells by in vitro activation and in vivo in HIV-infected patients Clin Exp Immunol 129 2002 119 124
24. V. Sanchez-Margalet, C. Martin-Romero, J. Santos-Alvarez, R. Goberna, S. Najib, and C. Gonzalez-Yanes Role of leptin as an immunomodulator of blood mononuclear cells: mechanisms of action Clin Exp Immunol 133 2003 11 19
25. V.W. Yong, S. Chabot, O. Stuve, and G. Williams Interferon beta in the treatment of multiple sclerosis: mechanisms of action Neurology 51 1998 682 689
26. V.W. Yong Differential mechanisms of action of interferon-beta and glatiramer acetate in MS Neurology 59 2002 802 808
27. J. Zhang, G. Hutton, and Y. Zang A comparison o f the mechanisms of action of interferon beta and glatiramer acetate in the treatment of multiple sclerosis Clin Ther 24 2002 1998 2021